CRTC1 (1B5) Antibody

MECT1 (MucoEpidermoid Carcinoma Translocated 1) is a transcriptional coactivator for CREB1. CREB1 activates transcription through both consensus and variant cAMP response element (CRE) sites. MECT1 does not appear to modulate CREB1 DNA-binding activity but enhances the interaction of CREB1 with TAF4/TAFII-130. MECT1 translocates with MAML2 (MasterMind-Like Protein 2) to yield a fusion oncogene: t(11;19) (q21;p13). This translocation occurs in mucoepidermoid carcinomas, benign Warthin tumors and clear cell hidradenomas. The novel fusion product that results disrupts the Notch signaling pathway. The fusion protein consists of the N-terminus of MECT1 joined to the C-terminus of MAML2. The reciprocal fusion protein consisting of the N-terminus of MAML2 joined to the C-terminus of MECT1 has been detected in a small number of mucoepidermoid carcinomas. MECT1 is highly e, Xenopus/Amphibian,pressed in adult and fetal brain. Located to specific regions such as the prefrontal corte, Xenopus/Amphibian, and cerebellum. Very low e, Xenopus/Amphibian,pression in other tissues such as heart, spleen, lung, skeletal muscle, salivary gland, ovary and kidney.